Human amniotic fluid stem cells as an attractive tool for clinical applications

Current Stem Cell Research and Therapy

Volumn 8, Issue 2, 2013, Pages 125-132

  Trohatou, Ourania ^a,b   Anagnou, Nicholas P ^a,b   Roubelakis, Maria G ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Amniotic fluid; Animal models; C kit; Cell transplantation; Fetal stem cells; Mscs; Stem cell therapy

Indexed keywords

FLUCYTOSINE; FLUOROURACIL;

ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ALLOTRANSPLANTATION; AMNIOTIC FLUID CELL; AMNIOTIC FLUID STEM CELL; ANTIINFLAMMATORY ACTIVITY; BLADDER DYSFUNCTION; BONE DEFECT; GENE TRANSFER; HEART INFARCTION; HUMAN; HUMAN CELL; IMMUNITY; LIMB ISCHEMIA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCIATIC NERVE INJURY; SKIN INJURY; STEM CELL; TERATOMA; VIRAL GENE DELIVERY SYSTEM;

AMNIOTIC FLUID; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84875606378     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X11308020003     Document Type: Review

References (50)

1. Daar AS, Greenwood HL. A proposed definition of regenerative medicine. J Tissue Eng Regen Med 2007; 1: 179-84.
2. Hipp J, Atala A. Sources of stem cells for regenerative medicine. Stem Cell Rev 2008; 4: 3-11.
3. Safinia L, Datan N, Hohse M, Mantalaris A, Bismarck A. Towards a methodology for the effective surface modification of porous polymer scaffolds. Biomaterials 2005; 26: 7537-47.
4. Towns CR, Jones DG. Stem cells, embryos, and the environment: a context for both science and ethics. J Med Ethics 2004; 30: 410-3.
5. Mason C, Brindley DA, Culme-Seymour EJ, Davie NL. Cell therapy industry: billion dollar global business with unlimited potential. Regen Med 2011; 6: 265-72.
6. Prusa AR, Hengstschlager M. Amniotic fluid cells and human stem cell research: a new connection. Med Sci Monit 2002; 8: RA253-7.
7. Roubelakis MG, Pappa KI, Bitsika V, et al. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 2007; 16: 931-52.
8. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003; 102: 1548-9.
9. Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod 2004; 19: 1450-6.
10. Tsai MS, Hwang SM, Tsai YL, et al. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod 2006; 74: 545-51.
11. De Coppi P, Bartsch G, Jr., Siddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007; 25: 100-6.
12. Roubelakis MG, Bitsika V, Zagoura D, et al. In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. J Cell Mol Med 2011; 15: 1896-913.
13. Leschot NJ, Verjaal M, Treffers PE. Risks of midtrimester amniocentesis; assessment in 3000 pregnancies. Br J Obstet Gynaecol 1985; 92: 804-7.
14. Eddleman KA, Malone FD, Sullivan L, et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006; 108: 1067-72.
15. Delo DM, De Coppi P, Bartsch G, Jr., Atala A. Amniotic fluid and placental stem cells. Methods Enzymol 2006; 419: 426-38.
16. Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells 2007; 25: 646-54.
17. Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschlager M. Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research? Hum Reprod 2003; 18: 1489-93.
18. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-301.
19. D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA. Agerelated osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res 1999; 14: 1115-22.
20. Moorefield EC, McKee EE, Solchaga L, et al. Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response. PLoS One 2011; 6: e26535.
21. Zagoura DS, Roubelakis MG, Bitsika V, et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut 2012; 61: 894-906.
22. Grisafi D, Piccoli M, Pozzobon M, et al. High transduction efficiency of human amniotic fluid stem cells mediated by adenovirus vectors. Stem Cells Dev 2008; 17: 953-62.
23. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-7.
24. Zucchelli M, Strom S, Holm F, et al. In vivo differentiated human embryonic stem cells (hESC) can acquire more frequently chromosomal aberrations than in vitro during the same period. Stem Cells Dev 2012.
25. Prokhorova TA, Harkness LM, Frandsen U, et al. Teratoma formation by human embryonic stem cells is site dependent and enhanced by the presence of Matrigel. Stem Cells Dev 2009; 18: 47-54.
26. Steindler DA. Stem cells, regenerative medicine, and animal models of disease. Ilar J 2007; 48: 323-38.
27. Zhao P, Ise H, Hongo M, et al. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation 2005; 79: 528-35.
28. Chiavegato A, Bollini S, Pozzobon M, et al. Human amniotic fluidderived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immunodeficient rat. J Mol Cell Cardiol 2007; 42: 746-59.
29. Delo DM, Guan X, Wang Z, et al. Calcification after myocardial infarction is independent of amniotic fluid stem cell injection. Cardiovasc Pathol 2011; 20: e69-78.
30. Cipriani S, Bonini D, Marchina E, et al. Mesenchymal cells from human amniotic fluid survive and migrate after transplantation into adult rat brain. Cell Biol Int 2007; 31: 845-50.
31. Pan HC, Chen CJ, Cheng FC, et al. Combination of G-CSF administration and human amniotic fluid mesenchymal stem cell transplantation promotes peripheral nerve regeneration. Neurochem Res 2009; 34: 518-27.
32. Pan HC, Chin CS, Yang DY, et al. Human amniotic fluid mesenchymal stem cells in combination with hyperbaric oxygen augment peripheral nerve regeneration. Neurochem Res 2009; 34: 1304-16.
33. Pan HC, Yang DY, Ho SP, et al. Escalated regeneration in sciatic nerve crush injury by the combined therapy of human amniotic fluid mesenchymal stem cells and fermented soybean extracts, Natto. J Biomed Sci 2009; 16: 75.
34. Cheng FC, Tai MH, Sheu ML, et al. Enhancement of regeneration with glia cell line-derived neurotrophic factor-transduced human amniotic fluid mesenchymal stem cells after sciatic nerve crush injury. J Neurosurg 2010; 112: 868-79.
35. Yang DY, Sheu ML, Su HL, et al. Dual regeneration of muscle and nerve by intravenous administration of human amniotic fluidderived mesenchymal stem cells regulated by stromal cell-derived factor-1alpha in a sciatic nerve injury model. J Neurosurg 2012; 116: 1357-67.
36. Perin L, Giuliani S, Jin D, et al. Renal differentiation of amniotic fluid stem cells. Cell Prolif 2007; 40: 936-48.
37. Perin L, Sedrakyan S, Giuliani S, et al. Protective effect of human amniotic fluid stem cells in an immunodeficient mouse model of acute tubular necrosis. PLoS One 2010; 5: e9357.
38. Hauser PV, De Fazio R, Bruno S, et al. Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery. Am J Pathol 2010; 177: 2011-21.
39. Rota C, Imberti B, Pozzobon M, et al. Human amniotic fluid stem cell preconditioning improves their regenerative potential. Stem Cells Dev 2012; 21: 1911-23.
40. Yoon BS, Moon JH, Jun EK, et al. Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchymal stem cells. Stem Cells Dev 2010; 19: 887-902.
41. Mirabella T, Hartinger J, Lorandi C, et al. Proangiogenic Soluble Factors from Amniotic Fluid Stem Cells Mediate the Recruitment of Endothelial Progenitors in a Model of Ischemic Fasciocutaneous Flap. Stem Cells Dev 2012; 21: 2179-88.
42. Mirabella T, Cilli M, Carlone S, Cancedda R, Gentili C. Amniotic liquid derived stem cells as reservoir of secreted angiogenic factors capable of stimulating neo-arteriogenesis in an ischemic model. Biomaterials 2011; 32: 3689-99.
43. Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009; 106: 4822-7.
44. Yin J, Kim JK, Moon JH, et al. hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. Mol Ther 2011; 19: 1161-9.
45. Bitsika V, Roubelakis MG, Zagoura D, et al. Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: a novel approach for the treatment of bladder cancer. Stem Cells Dev 2012; 21: 1097-111.
46. Kang NH, Hwang KA, Yi BR, et al. Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase in hibits the growth of breast cancer cells in cellular and xenograft mouse models. Cancer Gene Ther 2012; 19: 412-9.
47. Myers CE. The pharmacology of the fluoropyrimidines. Pharmacol Rev 1981; 33: 1-15.
48. Tomicic MT, Thust R, Kaina B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene 2002; 21: 2141-53.
49. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010; 16: 653-61.
50. Soler R, Fullhase C, Hanson A, et al. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol 2012; 187: 1491-7.